All Journals

Disseminates rigorous, original scholarship across the full spectrum of diabetology, from the molecular pathophysiology of type 2 diabetes mellitus, insulin resistance and beta-cell dysfunction to the clinical management of glycemic control, diabetic complications and metabolic disease. The journal welcomes work on prediabetes and incident diabetes, risk-factor epidemiology, diabetes prevention and screening, oral hypoglycemic agents and GLP-1 receptor agonists, diabetic nephropathy and chronic kidney disease, genome-wide association and polygenic studies, drug utilization evaluation, and health-related quality of life. We publish original research, systematic and narrative reviews, clinical case reports, and editorials that bridge bench, bedside and population health. JODR serves endocrinologists, diabetologists, nephrologists, clinical researchers, public-health scientists, pharmacologists and trainees seeking a trusted, internationally accessible venue. Every submission undergoes double-blind peer review by subject experts. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, indexed for discovery via OpenAlex and Google Scholar, and exposed through an OAI-PMH endpoint for harvesting. The journal follows COPE ethical principles, and article-processing charges apply on acceptance with waivers and discounts available.

Publishes original research, reviews, and case reports spanning the diagnosis, mechanisms, and management of endocrine and metabolic disease, with a translational emphasis that connects laboratory discovery to bedside practice for clinicians, endocrinologists, and biomedical researchers. Core coverage includes diabetes mellitus and incretin-based therapeutics (GLP-1 receptor agonists, tirzepatide, semaglutide), obesity and metabolic syndrome, and lipid and lipoprotein disorders such as dysbetalipoproteinemia. The journal has notable depth in adrenal disease and steroidogenesis, including congenital adrenal hyperplasia, primary adrenal insufficiency, and HPA-axis and cortisol dysregulation, alongside thyroid, pituitary, and reproductive endocrinology. We welcome studies using clinical trials, observational cohorts, endocrine diagnostics (immunoassays, imaging, ultrasonography), and emerging methods such as single-cell sequencing. Submissions are evaluated by rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons CC-BY 4.0 licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles.

Dedicated to clinical and translational scholarship across the breadth of urology. The journal serves urologists, surgeons, residents, and researchers by disseminating rigorous work on endourology and stone disease, uro-oncology, pediatric and congenital urology, reconstructive surgery, andrology, and urinary tract disorders. The journal welcomes original research, systematic reviews, clinical studies, surgical technique reports, and detailed case reports. Topics of core interest include percutaneous nephrolithotomy (PCNL), retrograde intrarenal surgery (RIRS), ureteroscopic lithotripsy and ureteric stricture, urolithiasis and pediatric nephrolithiasis, prostate and bladder cancer, testicular pathology, and minimally invasive and reconstructive urological techniques. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and are assigned a permanent Crossref DOI for citability and long-term preservation. Content is discoverable through OpenAlex and Google Scholar and exposed via an OAI-PMH endpoint for harvesting. Guided by COPE ethical principles, Annals of Urology aims to be a trusted, internationally accessible venue that advances urological evidence and practice while offering authors a transparent route to publication, with article-processing charges applied on acceptance and waivers or discounts available on request.

Advancing evidence across human nutrition, food safety, and food science. It serves nutritionists, dietitians, food scientists, technologists, and public-health researchers seeking a rigorous, internationally accessible venue for original work that links the laboratory bench to dietary practice and policy. The journal publishes research on food safety, quality, and adulteration (including milk and dairy authentication, contamination, and supply-chain integrity); functional foods, nutraceuticals, and bioactive compounds such as antioxidants and Moringa-derived ingredients; micronutrients and clinical nutrition, including iron-deficiency anemia and vitamin supplementation; and community and public-health nutrition spanning breastfeeding, child stunting, food security, and school feeding programs. Methodological contributions in food chemistry, physicochemical and shelf-life analysis, fortification, sensory evaluation, and analytical detection of adulterants are equally welcome. We accept original research, systematic and narrative reviews, case reports, short communications, and editorials. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) license with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles; an article-processing charge applies on acceptance, with waivers and discounts available.

Advances research, education, and clinical practice across the full spectrum of kidney medicine. It serves nephrologists, transplant clinicians, dialysis teams, renal scientists, and trainees worldwide, providing a trusted and freely accessible venue for original scholarship in nephrology. The journal welcomes original research, reviews, case reports, and editorials spanning chronic kidney disease and CKD staging, acute kidney injury, dialysis and hemodialysis, peritoneal dialysis, renal transplantation, glomerular and tubulointerstitial disease, electrolyte and acid-base disorders, renal physiology, and translational nephrology including biomarkers and single-cell transcriptomics of the kidney. We especially encourage clinically grounded studies on disease epidemiology, predictive factors and outcomes, renal infections such as pyelonephritis and urolithiasis, and innovations in renal replacement therapy. Both bench and bedside contributions, including instructive case reports, are within scope. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each article receives a permanent Crossref DOI and is made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint, ensuring citability and long-term preservation of the scholarly record.

Dedicated to advancing clinical and translational scholarship across the full spectrum of kidney diseases. As an open access kidney diseases journal, it provides a trusted, internationally accessible platform connecting nephrologists, transplant clinicians, dialysis teams, epidemiologists, and basic scientists. The journal welcomes original research, reviews, case reports, and editorials spanning chronic kidney disease (CKD), acute kidney injury, diabetic kidney disease, glomerular and tubulointerstitial disorders, hemodialysis and peritoneal dialysis adequacy (Kt/V, URR), kidney transplantation and recipient self-management, proteinuria, renal cell carcinoma, urinary stone disease, and the genetics of kidney disease. We also encourage work on care delivery and innovation, including intelligent automation in dialysis, machine learning in nephrology, and patient-centred outcomes research. Topics range from molecular mechanisms and biomarkers to population health, clinical epidemiology, and health-services evaluation. Every submission undergoes rigorous double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and are assigned a permanent Crossref DOI. Content is discoverable via OpenAlex and Google Scholar and exposed through an OAI-PMH endpoint, and the journal follows COPE ethical principles to safeguard the integrity of the scholarly record.

Advancing the science and clinical practice of hepatology and liver disease. It is an internationally accessible home for original research across hepatobiliary medicine, from molecular pathogenesis to bedside management. The journal welcomes basic, translational, and clinical studies on metabolic dysfunction-associated steatotic liver disease (MASLD/MASH), liver fibrosis and cirrhosis, hepatocellular carcinoma and bile duct tumors, viral hepatitis, cholestatic and autoimmune liver disease, portal hypertension, and liver transplantation. We publish original articles, reviews, case reports, and editorials, including non-invasive fibrosis assessment, imaging, and outcomes research. Every submission undergoes double-blind peer review. Accepted articles are published under a CC-BY 4.0 licence with authors retaining copyright, receive a permanent Crossref DOI, and are discoverable via OpenAlex, Google Scholar, and OAI-PMH, in line with COPE principles.

Dedicated to advancing gastroenterology and hepatology. It publishes original research, reviews, and case reports spanning the full spectrum of digestive and liver diseases, from the esophagus, stomach, and intestine to the liver, pancreas, and biliary tract. Core topics include inflammatory bowel disease (Crohn's disease and ulcerative colitis), irritable bowel syndrome, gastrointestinal bleeding, and digestive endoscopy, alongside hepatology themes such as non-alcoholic fatty liver disease (NAFLD/MASLD), viral hepatitis, liver cirrhosis and fibrosis, portal hypertension, and hepatocellular carcinoma. The journal also welcomes work on gastrointestinal oncology, pancreatobiliary disorders, and the gut microbiome. We value clinical, translational, and basic-science contributions, including epidemiological studies, randomized trials, diagnostic and biomarker research, and systematic reviews relevant to gastroenterologists, hepatologists, endoscopists, surgeons, and researchers worldwide. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI ensuring discoverability through OpenAlex, Google Scholar, and our OAI-PMH endpoint. The journal follows COPE ethical principles.

As a focused acute pancreatitis journal, it provides a dedicated home for research that is otherwise dispersed across general gastroenterology and surgery titles, serving gastroenterologists, pancreatobiliary endoscopists, surgeons, intensivists, radiologists, and translational scientists worldwide. The journal welcomes original research, systematic reviews, narrative reviews, case reports, and editorials across the full disease spectrum: etiology and biliary or gallstone pancreatitis, severity assessment and prognosis (BISAP, APACHE II, CRP and albumin biomarkers, the prognostic nutritional index, and machine-learning prediction models), early fluid resuscitation and nutrition, and the recognition of organ failure and systemic complications. A core editorial priority is interventional and endoscopic management, including ERCP, endoscopic ultrasound (EUS), EUS-guided drainage of pancreatic fluid collections and pseudocysts, lumen-apposing metal stents, and the step-up approach to necrotizing and infected pancreatic necrosis, alongside imaging advances such as CT severity indexing and FDG-PET. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence with authors retaining copyright, assigned a permanent Crossref DOI, and made discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles, with article-processing charges applied on acceptance and waivers or discounts available.

Advances the multidisciplinary science of obesity, from the molecular biology of white and brown adipose tissue to the clinical management of obesity-related metabolic disease, providing researchers, clinicians, and public-health practitioners a trusted venue for rigorous, citable scholarship. The journal welcomes original research, reviews, clinical trials, case reports, and editorials across adipose tissue biology, adipokine signalling, energy balance, and appetite regulation; metabolic syndrome, insulin resistance, type 2 diabetes, dyslipidemia, non-alcoholic fatty liver disease, and obesity-related cardiovascular disease; bariatric and metabolic surgery, anti-obesity pharmacotherapy including GLP-1 receptor agonists, and lifestyle and dietary interventions; and childhood obesity, obesity epidemiology, the gut microbiome, genetics, and prevention. We value translational work that bridges mechanism and patient care, alongside population studies that inform policy and weight-management practice. Methodological rigour, reproducibility, and transparent reporting are central to editorial assessment. Every submission undergoes double-blind peer review. Accepted articles are published open access under a Creative Commons Attribution (CC-BY 4.0) licence, with authors retaining copyright, and each receives a permanent Crossref DOI, discoverable through OpenAlex, Google Scholar, and an OAI-PMH endpoint. The journal follows COPE ethical principles.